Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Rheumatol Rep. 2011 Aug;13(4):300-7. doi: 10.1007/s11926-011-0180-z.

Treatment of cutaneous lupus.

Author information

  • 1Department of Dermatology, Perelman Center for Advanced Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. aileench@mail.med.upenn.edu

Abstract

Cutaneous lupus erythematosus (CLE) is an autoimmune inflammatory skin disease seen in patients with or without systemic lupus erythematosus. The management of CLE includes treatment and prevention of lesions as well as routine assessment for systemic disease. Treatment options include topical and systemic therapies. Topical therapies include corticosteroids and calcineurin inhibitors. Systemic therapies generally fall under one of three categories: antimalarials, immunomodulators (eg, dapsone and thalidomide), and immunosuppressives (eg, methotrexate and mycophenolate). Evidence for the treatment of CLE has been limited by few prospective studies and the lack of a validated outcome measure (until recently). There is good evidence to support the use of topical steroids and calcineurin inhibitors, although most of these trials have not used placebo or vehicle controls. There have been no randomized, placebo-controlled trials evaluating systemic therapies in the treatment of CLE.

PMID:
21503694
[PubMed - indexed for MEDLINE]
PMCID:
PMC3245840
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk